Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

Carmen Jimenez, Jose Francisco Lopez, Estela Garcia, Laura Diaz Regalado, Alejandro Panjkovich, Sophie Peng, Rama Krishna Narla, Noelia Purroy, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio

Blood (2024) 144 (Supplement 1): 1395.

https://doi.org/10.1182/blood-2024-210023

Published: 2024

Journal Articles

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Carmen Jimenez, Sophie Peng, Rama Krishna Narla, Joshua Baughman, Scott Wood, Jean Lu, Noelia Purroy, Gina Yanochko, Mark Nagy, Gang Lu, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio

Blood (2024) 144 (Supplement 1): 4142.

https://doi.org/10.1182/blood-2024-209924

Published: 2024

Journal Articles

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Blood (2022) 139 (14): 2252–2256.

https://doi.org/10.1182/blood.2021013926

Published: 2022

Includes: Supplemental data

Journal Articles

Genetic Determinants and Evolutionary History of Richter's Syndrome

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139456

Published: 2020

Journal Articles

T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation

Blood (2019) 134 (Supplement_1): 680.

https://doi.org/10.1182/blood-2019-125904

Published: 2019

Journal Articles

Single Cell Transcriptomic Characterization of the Immune Microenvironment in Naturally Progressing Chronic Lymphocytic Leukemia (CLL)

Noelia Purroy, MD PhD, Jean Fan, PhD, Shuqiang Li, Laura Z. Rassenti, PhD, James A Lederer, PhD, Donna S Neuberg, ScD, Thomas J. Kipps, MD PhD, Peter Kharchenko, PhD, Catherine J. Wu, MD

Blood (2018) 132 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2018-99-110931

Published: 2018

Journal Articles

Preben: Pixantrone, Rituximab, Etoposide and Bendamustine, Spanish Experience in Diffuse Large B-Cell Lymphoma Treatment

Cristina Barrenetxea Lekue, PhD, Clara Alonso Caballero, Laura Hernández Vázquez, Belen Navarro Matilla, Fco Javier Capote Huelva, Dolores Caballero, MD PhD, Noelia Purroy Zuriguel, Irene Leal Martinez, Daniela Caballero Alvarez, Jose Antonio Marquez Navarro, Fernando Marco de Lucas

Blood (2017) 130 (Supplement 1): 5235.

https://doi.org/10.1182/blood.V130.Suppl_1.5235.5235

Published: 2017

Journal Articles

XPO1 Inhibition By Selinexor Synergizes with BCR Inhibition, Blocks Tumor Growth and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma

Marta Crespo, Julia Carabia, Isabel Jiménez, Sabela Bobillo, Pau Abrisqueta, Carles Palacio, Cecilia Carpio, MD, Josep Castellvi, Noelia Purroy, Joan Seoane, Francesc Bosch, MD PhD

Blood (2016) 128 (22): 463.

https://doi.org/10.1182/blood.V128.22.463.463

Published: 2016

Journal Articles

Microrna Mir-21 Is Upregulated after Different Microenvironmental Stimuli and Controls Proliferation, Chemotaxis and Chemoresistance in Chronic Lymphocytic Leukemia

Marta Crespo, PhD, Júlia Carabia, Noelia Purroy, MD, Cecilia Carpio, MD, Pau Abrisqueta, MD, Carles Palacio, MD, Francesc Bosch, MD PhD

Blood (2014) 124 (21): 1971.

https://doi.org/10.1182/blood.V124.21.1971.1971

Published: 2014

Journal Articles

Syk Inhibition By TAK-659 Overcomes Proliferative, Survival and Migratory Signals from the Microenvironment in Chronic Lymphocytic Leukemia Cells

Noelia Purroy, MD, Pau Abrisqueta, MD, Júlia Carabia, Eva Calpe, PhD, Cecilia Carpio, MD, Carles Palacio, MD, Marta Crespo, PhD, Francesc Bosch, MD PhD

Blood (2014) 124 (21): 4698.

https://doi.org/10.1182/blood.V124.21.4698.4698

Published: 2014

Journal Articles

Regulation Of Microrna Mir-21 Expression By ZAP-70 Protein In Chronic Lymphocytic Leukemia

Marta Crespo, PhD, Cecilia Carpio, MD, Júlia Carabia, Pau Abrisqueta, MD, Eva Calpe, Noelia Purroy, MD, Carles Palacio, MD, Francesc Bosch, MD, PhD

Blood (2013) 122 (21): 4145.

https://doi.org/10.1182/blood.V122.21.4145.4145

Published: 2013

Journal Articles

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

Noelia Purroy, MD, Pau Abrisqueta, MD, Eva Calpe, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2013) 122 (21): 4153.

https://doi.org/10.1182/blood.V122.21.4153.4153

Published: 2013

Journal Articles

ZAP-70 Enhances Infiltration of Malignant B Lymphocytes Into the Bone Marrow by Increasing Migratory and Survival Responses to CXCR4 Stimulation

Marta Crespo, PhD, Eva Calpe, Noelia Purroy, MD, Cecilia Carpio, MD, Pau Abrisqueta, MD, Carles Palacio, MD, Josep Castellvi, MD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 1779.

https://doi.org/10.1182/blood.V120.21.1779.1779

Published: 2012

Journal Articles

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Noelia Purroy, MD, Pau Abrisqueta, MD, Eva Calpe, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3868.

https://doi.org/10.1182/blood.V120.21.3868.3868

Published: 2012

Journal Articles

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

Noelia Purroy, Juan Bergua, Laura Gallur, MD, Julio Prieto, Juan-Manuel Sancho, Luis Lopez, Jose A Garcia-Marco, Santiago Montes, Andres Lopez

Blood (2011) 118 (21): 593.

https://doi.org/10.1182/blood.V118.21.593.593

Published: 2011

Journal Articles

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Noelia Purroy, MD, Eva Calpe, Pau Abrisqueta, MD, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Josep Castellvi, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2011) 118 (21): 2844.

https://doi.org/10.1182/blood.V118.21.2844.2844

Published: 2011

Journal Articles

Differential Expression of Adhesion Molecules and Chemokine Receptors Confers Increased Migrative Capacity to ZAP-70-Positive Subclones in CLL Primary Cells,

Marta Crespo, PhD, Cecilia del Carmen Carpio, Eva Calpe, Pau Abrisqueta, MD, Carlos Palacio, Noelia Purroy, Francesc Bosch, MD, PhD

Blood (2011) 118 (21): 3889.

https://doi.org/10.1182/blood.V118.21.3889.3889

Published: 2011

Journal Articles

ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation

Eva Calpe, Carles Codony, Maria Joao Baptista, Pau Abrisqueta, Cecilia Carpio, Noelia Purroy, Francesc Bosch, Marta Crespo

Blood (2011) 118 (16): 4401–4410.

https://doi.org/10.1182/blood-2011-01-333682

Published: 2011

Includes: Multimedia, Supplemental data

Journal Articles

ZAP-70 Enhances BCR Signaling and Migration of Malignant B Lymphocytes towards CCL21 Via Induction of CCR7 Expression

Eva Calpe, Maria Joao Baptista, MSc, Carles Codony, PhD, Neus Villamor, MD, PhD, Pau Abrisqueta, MD, Olga Salamero, MD, Pere Barba, MD, Mercedes Gironella, MD, Noelia Purroy, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2010) 116 (21): 3591.

https://doi.org/10.1182/blood.V116.21.3591.3591

Published: 2010

Journal Articles

Title:Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Untreated Patients with Poor Risk Large B-Cell Lymphoma. A Phase 2 Study Conducted by the Spanish PETHEMA Group.

Noelia Purroy, Andrés López, Teresa Vallespi, MD.PhD., Mercedes Gironella, Juan Bergua, MD, Juan Manuel Sancho, MD

Blood (2009) 114 (22): 2701.

https://doi.org/10.1182/blood.V114.22.2701.2701

Published: 2009

NARROW

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Genetic Determinants and Evolutionary History of Richter's Syndrome

T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation

Single Cell Transcriptomic Characterization of the Immune Microenvironment in Naturally Progressing Chronic Lymphocytic Leukemia (CLL)

Preben: Pixantrone, Rituximab, Etoposide and Bendamustine, Spanish Experience in Diffuse Large B-Cell Lymphoma Treatment

XPO1 Inhibition By Selinexor Synergizes with BCR Inhibition, Blocks Tumor Growth and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma

Microrna Mir-21 Is Upregulated after Different Microenvironmental Stimuli and Controls Proliferation, Chemotaxis and Chemoresistance in Chronic Lymphocytic Leukemia

Syk Inhibition By TAK-659 Overcomes Proliferative, Survival and Migratory Signals from the Microenvironment in Chronic Lymphocytic Leukemia Cells

Regulation Of Microrna Mir-21 Expression By ZAP-70 Protein In Chronic Lymphocytic Leukemia

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

ZAP-70 Enhances Infiltration of Malignant B Lymphocytes Into the Bone Marrow by Increasing Migratory and Survival Responses to CXCR4 Stimulation

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Differential Expression of Adhesion Molecules and Chemokine Receptors Confers Increased Migrative Capacity to ZAP-70-Positive Subclones in CLL Primary Cells,

ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation

ZAP-70 Enhances BCR Signaling and Migration of Malignant B Lymphocytes towards CCL21 Via Induction of CCR7 Expression

Title:Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Untreated Patients with Poor Risk Large B-Cell Lymphoma. A Phase 2 Study Conducted by the Spanish PETHEMA Group.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only